×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Session 5: What Will Biosimilars Look Like in Five Years?
Session Chair(s)
Anna Welch, MA
Chief Editor, Biosimilar Development
Life Science Connect, United States
As biosimilar stakeholders evaluate the appropriate metrics of success for the current wave of products, it’s important to consider how the industry’s market dynamics may shift in the future. Looking ahead, there are several critical questions to consider, including:
- Which company models will be best suited for the future market, and why?
- What types of products will be chosen as future biosimilar development candidates?
- What development challenges will these products pose for companies?
- How will companies strive to differentiate their biosimilar products or development process?
Learning Objective : At the conclusion of this session, participants should be able to:
- Evaluate the next wave of the biosimilar pipeline and the opportunities/challenges it will pose for the industry
- Understand best business practices (i.e., product selection and differentiation strategies) that can be employed to remain in the biosimilar market long-term
- Evaluate novel manufacturing and outsourcing strategies to reduce COGs
Speaker(s)
Speaker
Murray Aitken, MBA
IQVIA Institute for Human Data Science, United States
Executive Director
Speaker
Michiel Ultee, PhD, MS
Ulteemit Bioconsulting, United States
Principal
Speaker
Alexandra Moulson, MBA, MS
Polpharma Biologics, Poland
VP Strategy, Programs and Portfolio
Speaker
George I'ons
Owen Mumford, Ltd, United Kingdom
Head of Product Strategy & Insights
Have an account?